{"analyses":[{"ciLowerLimit":"1.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0168","paramType":"Odds Ratio (OR)","paramValue":"1.28","statisticalMethod":"Proportional Odds Model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.0","upperLimit":"55.2","value":"51.6"},{"groupId":"OG001","lowerLimit":"52.7","upperLimit":"59.9","value":"56.3"}]}],"title":"Day 14 NIAID-OS 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.9","upperLimit":"13.5","value":"11.2"},{"groupId":"OG001","lowerLimit":"8.8","upperLimit":"13.4","value":"11.1"}]}],"title":"Day 14 NIAID-OS 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.6","value":"0.3"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.4","value":"0.1"}]}],"title":"Day 14 NIAID-OS 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"10.0","value":"8.0"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"9.6","value":"7.6"}]}],"title":"Day 14 NIAID-OS 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"10.5","value":"8.4"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"9.2","value":"7.3"}]}],"title":"Day 14 NIAID-OS 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"4.9","value":"3.6"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"5.1","value":"3.7"}]}],"title":"Day 14 NIAID-OS 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"11.6","value":"9.4"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"11.0","value":"8.9"}]}],"title":"Day 14 NIAID-OS 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"9.4","value":"7.5"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"6.5","value":"4.9"}]}],"title":"Day 14 NIAID-OS 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"762"}],"units":"Participants"}],"description":"Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale:\n\n1\\. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.","reportingStatus":"POSTED","timeFrame":"Day 14","title":"Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14","type":"SECONDARY","unitOfMeasure":"percentage of participants"}